Topical Green Tea Ointment in Treatment of Superficial Skin Cancer
Launched by MAASTRICHT UNIVERSITY MEDICAL CENTER · Jan 6, 2014
Trial Information
Current as of May 14, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adults aged 18 years or older
- • Primary histological proven superficial basal cell carcinoma ≥ 4mm and ≤ 20mm
- • Comorbidities may not interfere with study treatment (evaluated by investigator)
- • Capable to understand instructions
- Exclusion Criteria:
- • Recurrent sBCC (previous treatment)
- • Breast-feeding or pregnant women
- • Serious comorbidities
- • Use of immunosuppressive medication during the trial period or within 30 days before enrolment
- • Patients with genetic skin cancer disorders
- • Tumour located in the H zone (high-risk area of face) or scalp
About Maastricht University Medical Center
Maastricht University Medical Center (MUMC+) is a leading academic medical center in the Netherlands, renowned for its commitment to advancing healthcare through innovative research and education. As a prominent sponsor of clinical trials, MUMC+ integrates cutting-edge scientific inquiry with clinical practice, focusing on a wide range of medical disciplines. The center emphasizes collaboration among multidisciplinary teams, fostering an environment that promotes excellence in patient care and the translation of research findings into clinical applications. MUMC+ is dedicated to improving health outcomes and enhancing quality of life through rigorous clinical investigations and the development of novel therapeutic strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Maastricht, Limburg, Netherlands
Patients applied
Trial Officials
Nicole WJ Kelleners-Smeets, MD, PhD
Principal Investigator
Maastricht University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials